Xconomy: Adaptive Reels in Whopping $195M For Immuno-Sequencing Work
Summary
Adaptive Reels in Whopping $195M For Immuno-Sequencing Work Xconomy Seattle — [Updated, 5/7/15, 11:10 am ET] Adaptive Biotechnologies of Seattle is continuing its busy year, announcing this morning it has reeled it $195 million in financing from a group of new investors.The big cash haul comes four months after the sequencing company, which specializes in understanding the immune system, raised $94 million to help buy a rival, Sequenta.Existing investors Viking Global, Casdin Capital and Alexandria Real Estate Equities also joined the round.Viking is a Greenwich, CT-based hedge fund that put in $200 million across Adaptive’s two previous financings.Cancer is a pathogen, too, but tumor cells have a myriad of ways to thwart or evade the immune system, which makes technology like Adaptive’s—which offers deep dives and analyses of people’s ever-changing immune systems—potentially invaluable both to doctors who want to diagnose and treat patients, and to researchers looking to make better, more targeted treatments for cancer and other diseases.
Classifications
AskAI Classifications
LabelsLinked Companies
